When Sanofi bought Genzyme, the deal was clinched on a contingent value right (CVR) based on the potential multiple sclerosis treatment Lemtrada. Could Pfizer do the same thing to win over AstraZeneca?
written on 16.06.2014
Could Pfizer nab AstraZeneca with pipeline-based payouts? Maybe, but cash is easier
